This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
Phippen NT, et al. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective? Gynecologic Oncology : 9 Nov 2014. Available from: URL: http://doi.org/10.1016/j.ygyno.2014.11.003
Rights and permissions
About this article
Cite this article
Bevacizumab in cervix cancer: improved outcomes at a cost. PharmacoEcon Outcomes News 718, 12 (2014). https://doi.org/10.1007/s40274-014-1777-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1777-z